Category: Apollo EndosurgerySyndicate content

Obesity: Allergan finalizes Lap-Band division sale

December 3, 2013 by Arezu Sarvestani

Apollo Endosurgery closes the books on its acquisition of Allergan's obesity intervention business, including the Lap-Band and Orbera technologies, in a deal worth up to $110 million.

Allergan finalizes Lap-Band division sale

Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Apollo Endosurgery to buy Allergan's obesity biz for up to $110M

October 29, 2013 by Brad Perriello

Apollo Endosurgery inks a deal with Allergan to acquire its obesity intervention business for up to $110 million.

Apollo Endosurgery to buy Allergan's obesity biz for up to $110M

Almost exactly 1 year after saying it would seek a buyer for its Lap-Band obesity device, Allergan (NYSE:AGN) said today that Apollo Endosurgery agreed to spend up to $110 million on Allergan's obesity intervention business, which includes the Orbera intra-gastric balloon.

AngioDynamics details $372M Navilyst buyout details | Wall Street Beat

February 8, 2012 by MassDevice staff

The $372 million buyout of Navilyst medical is expected to add 8 cents per share to AngioDynamics' books during fiscal 2013; also, Orasi Medical closes up shop; Becton, Dickinson reveals medical device tax impact; Abiomed hits 52-week high; analysts' ups and downs; and the Funding Roundup. Wall Street Beat

Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp